ResMed (RMD) Set to Announce Earnings on Thursday

ResMed (NYSE:RMD) will be posting its quarterly earnings results after the market closes on Thursday, April 25th. Analysts expect ResMed to post earnings of $1.93 per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

ResMed (NYSE:RMD) last posted its quarterly earnings results on Wednesday, January 24th. The medical equipment provider reported $1.88 earnings per share for the quarter, topping analysts’ consensus estimates of $1.81 by $0.07. ResMed had a return on equity of 23.86% and a net margin of 19.77%. The business had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.15 billion. During the same period in the prior year, the business earned $1.66 EPS. The firm’s revenue for the quarter was up 12.5% on a year-over-year basis. On average, analysts expect ResMed to post $7 EPS for the current fiscal year and $8 EPS for the next fiscal year.

ResMed Trading Down 6.0 %

Shares of ResMed stock opened at $173.86 on Thursday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.89 and a current ratio of 3.11. ResMed has a 52 week low of $132.24 and a 52 week high of $243.52. The stock has a 50 day moving average price of $186.42 and a two-hundred day moving average price of $170.17. The stock has a market capitalization of $25.57 billion, a PE ratio of 28.74, a price-to-earnings-growth ratio of 2.29 and a beta of 0.67.

ResMed Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 14th. Investors of record on Thursday, February 8th were given a $0.48 dividend. This represents a $1.92 annualized dividend and a yield of 1.10%. The ex-dividend date was Wednesday, February 7th. ResMed’s payout ratio is currently 31.74%.

Insider Buying and Selling at ResMed

In related news, Director Peter C. Farrell sold 10,935 shares of the company’s stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $182.66, for a total value of $1,997,387.10. Following the transaction, the director now owns 157,404 shares in the company, valued at $28,751,414.64. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, Director Peter C. Farrell sold 10,935 shares of ResMed stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $182.66, for a total value of $1,997,387.10. Following the completion of the sale, the director now owns 157,404 shares of the company’s stock, valued at approximately $28,751,414.64. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, General Counsel Michael J. Rider sold 200 shares of the business’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $173.25, for a total value of $34,650.00. Following the completion of the sale, the general counsel now owns 6,688 shares in the company, valued at $1,158,696. The disclosure for this sale can be found here. Insiders have sold a total of 11,216 shares of company stock worth $2,046,617 over the last three months. 1.21% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. FIL Ltd boosted its stake in ResMed by 245.9% in the 4th quarter. FIL Ltd now owns 840,030 shares of the medical equipment provider’s stock worth $144,502,000 after purchasing an additional 597,165 shares during the period. Public Employees Retirement System of Ohio boosted its position in shares of ResMed by 2.8% in the fourth quarter. Public Employees Retirement System of Ohio now owns 60,833 shares of the medical equipment provider’s stock valued at $10,464,000 after acquiring an additional 1,662 shares during the period. Kensington Investment Counsel LLC boosted its position in shares of ResMed by 1.4% in the fourth quarter. Kensington Investment Counsel LLC now owns 9,366 shares of the medical equipment provider’s stock valued at $1,611,000 after acquiring an additional 133 shares during the period. Legal & General Group Plc grew its stake in ResMed by 12.2% during the fourth quarter. Legal & General Group Plc now owns 1,122,245 shares of the medical equipment provider’s stock valued at $193,049,000 after acquiring an additional 122,167 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in ResMed by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 17,743,457 shares of the medical equipment provider’s stock worth $3,052,229,000 after acquiring an additional 173,635 shares during the period. 54.98% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

RMD has been the subject of a number of analyst reports. UBS Group lifted their price target on ResMed from $175.00 to $180.00 and gave the company a “neutral” rating in a research note on Thursday, January 25th. Mizuho reaffirmed a “buy” rating and set a $215.00 price objective on shares of ResMed in a report on Wednesday, March 27th. Oppenheimer increased their target price on shares of ResMed from $185.00 to $205.00 and gave the company an “outperform” rating in a report on Tuesday, January 30th. Needham & Company LLC raised their price target on shares of ResMed from $215.00 to $224.00 and gave the company a “buy” rating in a research report on Monday, April 1st. Finally, KeyCorp began coverage on shares of ResMed in a research report on Tuesday, February 6th. They issued an “overweight” rating and a $227.00 price objective for the company. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, ResMed presently has a consensus rating of “Moderate Buy” and a consensus target price of $199.20.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.